Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 17, 2017
Which drugs does patent 9,000,021 protect, and when does it expire?
| Title: | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
| Abstract: | Methods of treating bendamustine responsive conditions in patients having fluid and/or sodium intake restrictions are disclosed. The methods include identifying patients having such restrictions and in need of bendamustine, and then administering thereto a bendamustine-containing composition in a volume of about 120 ml or less intravenously over a period of about 15 minutes or less. The smaller volumes and reduced sodium load as compared to currently known methods of treatment minimize cardiac and/or renal stress in patients having diseases such as congestive heart failure or renal disease. |
| Inventor(s): | Sundaram; Srikanth (Somerset, NJ), Tarriff; Scott L. (Mahwah, NJ) |
| Assignee: | Eagle Pharmaceuticals, Inc. (Woodcliff Lake, NJ) |
| Application Number: | 13/838,267 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Delivery; |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eagle Pharms | BENDEKA | bendamustine hydrochloride | SOLUTION;IV (INFUSION) | 208194-001 | Dec 7, 2015 | RX | Yes | Yes | ► Subscribe | ► Subscribe | FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA | ||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9,579,384 | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | ► Subscribe | |||||||||||||
| 9,034,908 | Formulations of bendamustine | ► Subscribe | |||||||||||||
| 9,597,399 | Formulations of bendamustine | ► Subscribe | |||||||||||||
| 9,572,887 | Formulations of bendamustine | ► Subscribe | |||||||||||||
| 9,572,888 | Formulations of bendamustine | ► Subscribe | |||||||||||||
| 9,597,397 | Formulations of bendamustine | ► Subscribe | |||||||||||||
| 9,144,568 | Formulations of bendamustine | ► Subscribe | |||||||||||||
| 9,597,398 | Formulations of bendamustine | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Canada | 2867295 | ► Subscribe | |||||||||||||
| Canada | 2867343 | ► Subscribe | |||||||||||||
| China | 104271135 | ► Subscribe | |||||||||||||
| China | 104302291 | ► Subscribe | |||||||||||||
| China | 107157988 | ► Subscribe | |||||||||||||
| European Patent Office | 2827862 | ► Subscribe | |||||||||||||
| European Patent Office | 2827863 | ► Subscribe | |||||||||||||
| Japan | 2015510939 | ► Subscribe | |||||||||||||
| Japan | 2015510940 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 2013142358 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,914 others who get our Drug Patent Expiration Alerts:
